Breaking News & Top Stories
The US Food and Drug Administration (FDA) has instructed drug manufacturers Novo Nordisk and Eli Lilly to eliminate warnings regarding potential suicidal thoughts and behaviors from their widely used weight-loss…
Arrowhead Pharmaceuticals announced promising early results from its gene-silencing drug, ARO-INHBE, which has demonstrated significant weight loss effects in individuals with obesity. In a Phase 1/2 study, patients receiving two…
Pharmaceutical companies are set to increase the prices of at least 350 branded medications in the United States, including vaccines for COVID-19, respiratory syncytial virus (RSV), shingles, and the cancer…
The Food and Drug Administration (FDA) has approved the oral version of Novo Nordisk’s weight loss medication, Wegovy. This marks the first time a GLP-1 pill has received regulatory clearance…
President Donald Trump has announced agreements with drug manufacturers Eli Lilly and Novo Nordisk aimed at reducing prices for GLP-1 weight-loss medications under Medicare and Medicaid. This move is part…
Viewers of *World News Tonight* with David Muir were surprised this week as the anchor detailed a new agreement between the administration of former President Donald Trump and two major…
Eli Lilly and Novo Nordisk are poised to announce agreements with the White House that could significantly reduce the cost of their obesity medications. Reports indicate that the companies will…
President Donald Trump has taken a firm stance on prescription drug prices, sending letters to 17 pharmaceutical companies urging them to lower their prices to match the lowest rates offered…
A series of developments are reshaping the landscape of the pharmaceutical industry, as major players grapple with challenges and opportunities. Novo Nordisk, a leader in diabetes care, continues to navigate…
BREAKING: Novo Nordisk has just announced a significant restructuring plan aimed at revitalizing its long-term investment strategy in diabetes and obesity treatments. The pharmaceutical giant is adjusting its 2025 operating…